They are as follows: Prevention — These trials test new interventions that may lower the risk of developing cancer.
Most cancer prevention trials involve healthy people who have not had cancer; however, they often only include people who have a higher than average risk of developing a specific type of cancer.
These studies also may show which medical approaches work best for certain illnesses or groups of individuals.
Ovarian cancer clinical trials are designed to test new ways to: Ovarian cancer clinical trials are broken down into 4 separate categories.
As the world’s fourth largest CRO, PRA is transforming clinical trials through our people, innovation and transparency.
SPRI’s key criteria for clinical study site selection includes: If you review our feasibility numbers against our actual clinical trial enrollment statistics, you’ll find that SPRI has a history of exceeding enrollment expectations.
We believe that through ongoing support, our clinical team creates an environment of success.
In this webinar, the speakers will discuss through case examples ways to accelerate enrollment across the continuum of protocol development to activation by: Martin Lee received his medical degree from the University of Texas Medical School at Houston and is board certified in medical oncology. Lee has 19 years of clinical experience in the front-line care of hematology and oncology patients and has also served as an Institutional Review Board chairman and leader of a clinical research program in academic and community settings. Lee’s interests include the study of oncology drug development, clinical trial feasibility and optimizing patient recruitment to clinical trials. Lee oversees PRA’s feasibility and site identification groups and is launching an innovative clinical trial liaison program that is modeled after the success of medical science liaison programs in the pharmaceutical industry.
Gretchen has amassed over 15 years of clinical research experience, including the start of her career as a study coordinator and then as a Site Director at the University of Pennsylvania in various therapeutic areas including ophthalmology, women's health, HIV/AIDS, cardiology and endocrinology. Prior to this, she served as a contract Clinical Trial Manager at Wyeth in the Global Medical Affairs vaccines group and Astra Zeneca as a study manager in cardiology.